Insider Transactions in Q3 2021 at Aprea Therapeutics, Inc. (APRE)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 20
2021
|
Lars B. Abrahmsen SVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
25,000
-56.82%
|
$100,000
$4.97 P/Share
|
|
Sep 20
2021
|
Lars B. Abrahmsen SVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+36.23%
|
$0
$0.92 P/Share
|
|
Sep 20
2021
|
Gregory Alan Korbel SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
32,960
-42.85%
|
$131,840
$4.98 P/Share
|
|
Sep 20
2021
|
Gregory Alan Korbel SVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,500
+38.11%
|
$0
$0.92 P/Share
|
|
Sep 16
2021
|
Eyal C. Attar SVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,968
-16.13%
|
$63,872
$4.68 P/Share
|
|
Sep 10
2021
|
Gregory Alan Korbel SVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,724
-7.08%
|
$6,896
$4.59 P/Share
|
|
Aug 25
2021
|
Eyal C. Attar SVP, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,032
-8.36%
|
$27,096
$3.98 P/Share
|
|
Aug 25
2021
|
Scott M Coiante SVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,534
-7.61%
|
$22,602
$3.98 P/Share
|
|
Aug 25
2021
|
Gregory Alan Korbel SVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,149
-4.51%
|
$3,447
$3.98 P/Share
|